Linked Life Data

17917307

Source:http://linkedlifedata.com/resource/pubmed/id/17917307

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2008-2-20
pubmed:abstractText
It has been well established that raloxifene (RLX) has beneficial effects on bone primarily in Caucasian women. However, to date, there is a dearth of data for Japanese postmenopausal women. In this study, we prospectively evaluated the effects of RLX on bone and lipid metabolism in fifty Japanese postmenopausal patients with untreated osteoporosis. We measured bone mineral density (BMD) by dual-energy X-ray absorptiometry at 7 sites including the lumbar spine, femoral neck, and distal radius. BMD was significantly increased at the lumbar spine both at 6 months and at 12 months compared with at baseline (p<0.01 for both), although the possibility could not be completely excluded that this increase may be partly explained by an apparent increase induced by degenerative changes in lumbar vertebrae since we had no control subjects to compare and be more certain of the findings in this study. Both bone-specific alkaline phosphatase (BAP) and serum N-terminal telopeptide of type I collagen (NTx) significantly decreased both at 6 months (p<0.01 for both) and at 12 months (p<0.01 for both) compared with at baseline, but not below the lower limit of the reference value. Total cholesterol and low-density lipoprotein cholesterol were significantly improved while triglycerides and high-density lipoprotein cholesterol were unaltered. Although longer and larger studies with fracture endpoints are needed to draw definite conclusions, our findings suggest the favorable effects of RLX on bone and lipid metabolism in Japanese postmenopausal women with osteoporosis as in Caucasian women.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1348-4540
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
54
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
855-62
pubmed:dateRevised
2011-6-16
pubmed:meshHeading
pubmed-meshheading:17917307-Aged, pubmed-meshheading:17917307-Aged, 80 and over, pubmed-meshheading:17917307-Alkaline Phosphatase, pubmed-meshheading:17917307-Bone Density, pubmed-meshheading:17917307-Bone Density Conservation Agents, pubmed-meshheading:17917307-Bone and Bones, pubmed-meshheading:17917307-Cholesterol, LDL, pubmed-meshheading:17917307-Collagen Type I, pubmed-meshheading:17917307-Female, pubmed-meshheading:17917307-Humans, pubmed-meshheading:17917307-Japan, pubmed-meshheading:17917307-Lipid Metabolism, pubmed-meshheading:17917307-Longitudinal Studies, pubmed-meshheading:17917307-Middle Aged, pubmed-meshheading:17917307-Osteoporosis, Postmenopausal, pubmed-meshheading:17917307-Peptides, pubmed-meshheading:17917307-Postmenopause, pubmed-meshheading:17917307-Prospective Studies, pubmed-meshheading:17917307-Raloxifene, pubmed-meshheading:17917307-Triglycerides
pubmed:year
2007
pubmed:articleTitle
Clinical significance of 1-year treatment with raloxifene on bone and lipid metabolism in Japanese postmenopausal women with osteoporosis.
pubmed:affiliation
Division of Metabolic Research, Clinical Research Institute, Center for Endocrine and Metabolic Diseases, National Hospital Organization, Kyoto Medical Center, Kyoto, Japan.
pubmed:publicationType
Journal Article, Clinical Trial